Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2024-04 · 16 (2)
DOI: 10.1002/dad2.12589 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, online erschienen am 25.04.2024. Verfasst von Lara Blömeke und 47 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biological Information Processing (Structural Biochemistry: IBI-7) Forschungszentrum Jülich GmbH Jülich Germany. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, ALS Association, Deutsche Forschungsgemeinschaft.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Soluble amyloid beta (Aβ) oligomers have been suggested as initiating Aβ related neuropathologic change in Alzheimer's disease (AD) but their quantitative distribution and chronological sequence within the AD continuum remain unclear. METHODS A total of 526 participants in early clinical stages of AD and controls from a longitudinal cohort were neurobiologically classified for amyloid and tau pathology applying the AT(N) system. Aβ and tau oligomers in the quantified cerebrospinal fluid (CSF) were measured using surface‐based fluorescence intensity distribution analysis (sFIDA) technology. RESULTS Across groups, highest Aβ oligomer levels were found in A+ with subjective cognitive decline and mild cognitive impairment. Aβ oligomers were significantly higher in A+T− compared to A−T− and A+T+. APOE ε 4 allele carriers showed significantly higher Aβ oligomer levels. No differences in tau oligomers were detected. DISCUSSION The accumulation of Aβ oligomers in the CSF peaks early within the AD continuum, preceding tau pathology. Disease‐modifying treatments targeting Aβ oligomers might have the highest therapeutic effect in these disease stages. Highlights Using surface‐based fluorescence intensity distribution analysis (sFIDA) technology, we quantified Aβ oligomers in cerebrospinal fluid (CSF) samples of the DZNE‐Longitudinal Cognitive Impairment and Dementia (DELCODE) cohort Aβ oligomers were significantly elevated in mild cognitive impairment (MCI) Amyloid‐positive subjects in the subjective cognitive decline (SCD) group increased compared to the amyloid‐negative control group Interestingly, levels of Aβ oligomers decrease at advanced stages of the disease (A+T+), which might be explained by altered clearing mechanisms
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Biological Information Processing (Structural Biochemistry: IBI-7) Forschungszentrum Jülich GmbH Jülich Germany.
- attyloid GmbH Düsseldorf Germany.
- Institut für Physikalische Biologie Heinrich-Heine-Universität Düsseldorf Düsseldorf Germany.
- Department of Psychiatry and Psychotherapy Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg Erlangen Germany.
- Department of Psychiatry and Psychotherapy Charité Berlin Germany.
- German Center for Neurodegenerative Diseases (DZNE) Berlin Germany.
Förderung
- NIA NIH HHS
- ALS Association
- Deutsche Forschungsgemeinschaft
- Helmholtz Association
Zitieren
APA
Blömeke, L., Rehn, F., Kraemer-Schulien, V., Kutzsche, J., Pils, M., Bujnicki, T., Lewczuk, P., Kornhuber, J., Freiesleben, S. D., Schneider, L. S., Preis, L., Priller, J., Spruth, E. J., Altenstein, S., Lohse, A., Schneider, A., Fliessbach, K., Wiltfang, J., Hansen, N., …, & Peters, O. (2024). Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 16(2). https://doi.org/10.1002/dad2.12589
Vancouver
Blömeke L, Rehn F, Kraemer-Schulien V, Kutzsche J, Pils M, Bujnicki T, et al. Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2024;16(2). doi:10.1002/dad2.12589
BibTeX
@article{Blmeke2024,
author = {Blömeke, Lara and Rehn, Fabian and Kraemer-Schulien, Victoria and Kutzsche, Janine and Pils, Marlene and Bujnicki, Tuyen and Lewczuk, Piotr and Kornhuber, Johannes and Freiesleben, Silka D and Schneider, Luisa-Sophie and Preis, Lukas and Priller, Josef and Spruth, Eike J and Altenstein, Slawek and Lohse, Andrea and Schneider, Anja and Fliessbach, Klaus and Wiltfang, Jens and Hansen, Niels and Rostamzadeh, Ayda and Düzel, Emrah and Glanz, Wenzel and Incesoy, Enise I and Butryn, Michaela and Buerger, Katharina and Janowitz, Daniel and Ewers, Michael and Perneczky, Robert and Rauchmann, Boris-Stephan and Teipel, Stefan and Kilimann, Ingo and Goerss, Doreen and Laske, Christoph and Munk, Matthias H and Sanzenbacher, Carolin and Spottke, Annika and Roy-Kluth, Nina and Heneka, Michael T and Brosseron, Frederic and Wagner, Michael and Wolfsgruber, Steffen and Kleineidam, Luca and Stark, Melina and Schmid, Matthias and Jessen, Frank and Bannach, Oliver and Willbold, Dieter and Peters, Oliver},
title = {Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology},
journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
year = {2024},
volume = {16},
number = {2},
doi = {10.1002/dad2.12589}
}
EUVIMED